喹硫平联合丙戊酸镁缓释片治疗癔症性精神病对照研究

A control study of quetiapine combined with magnesium val-proate sustained-release tablets in the treatment of patients with hysterical psychosis

目的：探讨富马酸喹硫平联合丙戊酸镁缓释片治疗癔症性精神病患者的临床疗效和安全性。方法将65例癔症性精神病患者随机分为两组，研究组口服富马酸喹硫平联合丙戊酸镁缓释片治疗，对照组口服富马酸喹硫平治疗，观察4周。采用大体评定量表评定临床疗效，副反应量表评定不良反应。结果研究组起效时间显著早于对照组（ t＝8．59，P＜0．01）；治疗4周末痊愈率显著高于对照组（χ^2＝4．78，P＜0．05）；两组不良反应多出现在治疗初期，不良反应发生率比较差异无显著性（χ^2＝0．15，P＞0．05）。结论富马酸喹硫平联合丙戊酸镁缓释片治疗癔症性精神病患者疗效显著，起效快，安全性高，优于单用富马酸喹硫平治疗。

Objective To explore the efficacy and safety of quetiapine fumarate combined with magnesium valproate sustained-release tablets （MVST） in the treatment of patients with hysterical psychosis .Methods Sixty-five patients with hysterical psychosis were randomly assigned to two groups ,research group took o-rally quetiapine fumarate plus MVST and control did quetiapine fumarate for 4 weeks .Efficacies were as-sessed with the Global Assessment Scale （GAS ） and adverse reactions with the Treatment Emergent Symptoms Scale （TESS） .Results Research group took effect more rapidly than control did （t=8 .59 ,P〈0 .01）;cure rate was significantly higher in research than control group at the end of 4 weeks （χ^2 =4 .78 , P〈0 .05）;adverse reactions of both groups emerged mainly in the early days of treatment ,there were no group significant incidences of adverse reactions （χ^2 =0 .15 ,P〉0 .05） .Conclusion Quetiapine fumarate combined with MVST has an evident effect ,takes effect more rapidly and has higher safety compared with single quetiapine fumarate in the treatment of hysterical psychosis .